MAYNE PHARMA LAUNCHES DOXYCYCLINE IR CAPSULES IN THE US, GENERIC MONODOX

March 15, 2018, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the launch of doxycycline monohydrate immediate release (IR) capsules (50mg, 75mg and 100mg) in the United States. Doxycycline IR capsules are a generic alternative to Monodox®, a tetracycline-class antibacterial indicated for the treatment of a number of infections, including adjunctive therapy in severe acne.

Mayne Pharma’s CEO Scott Richards said, “This launch will further broaden Mayne Pharma’s dermatology portfolio of branded and generic products. Mayne Pharma is committed to helping patients and physicians cost-effectively manage various skin conditions including acne and psoriasis.”

Mayne Pharma directly markets more than 55 products and has a growing pipeline of around 30 drug products targeting U.S. markets with IQVIA sales greater than $5 billion. According to IQVIA, annual U.S. sales of doxycycline IR capsules were approximately $30 million for the 12 months ending Jan. 31, 2018.

Important Safety Information Regarding Doxycycline Capsules, 50mg, 75mg & 100mg

Doxycycline is contraindicated in patients who have shown hypersensitivity to any of the tetracyclines. Tetracycline-class drugs, like doxycycline capsules, can cause fetal harm when administered to a pregnant woman. Doxycycline capsules should be avoided if possible by nursing mothers, taking into account the importance of the drug to the mother. Doxycycline capsules should not be used in children during tooth development (up to the age of 8 years). Concurrent use of tetracycline-class antibiotics with oral contraceptives may reduce their effectiveness.

Full prescribing information, including warnings, can be found [here](http://www.maynepharma.com). To report a suspected adverse reaction from one of our products, please contact Mayne Pharma at 1-844-825-8500 or maynepharma@dlss.com, or the FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

For further information contact:
Lisa Pendlebury       +61 419 548 434, lisa.pendlebury@maynepharma.com

About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialize branded and generic pharmaceuticals. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide. Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world.

Mayne Pharma has two product development and manufacturing facilities based in Salisbury, Australia and Greenville, N.C., USA, with expertise in formulation complex oral dose forms including highly potent compounds, controlled substances, modified release products and inherently unstable compounds.

Monodox® is a registered trademark of Aqua Pharmaceuticals, LLC.